Torrent Pharma

Ahmedabad, India Founded: 1959 • Age: 67 yrs Listed Fortune India 500 · #229
Formulations, APIs, drug discovery, marketing, and sales services are provided.
Request Access
Report Incorrect Data
Page last updated

About Torrent Pharma

Torrent Pharma is a publicly listed company based in Ahmedabad (India) founded in 1959 by Chirag Patel. Formulations, APIs, drug discovery, marketing, and sales services are provided. The company has 16,012 employees. Torrent Pharma has completed 3 acquisitions, including Bio-Pharm, Curatio healthcare and JB. Its chief executive, as recorded, is Chirag Patel. Its website torrentpharma.com draws about 32 thousand monthly visits. Its Indian entity Torrent Pharmaceuticals Ltd reported revenue of ₹10,730 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Torrent Pharma was established in 1959 in Ahmedabad, India, within the pharmaceutical sector. Formulations and active pharmaceutical ingredients (APIs) are developed, alongside drug discovery efforts. Marketing and sales operations are managed to support product distribution. Services extend across domestic and international markets, with the companys online presence maintained at torrentpharma.com. Leadership is provided by founder and CEO Chirag Patel.

Torrent Pharma is ranked #229 on the Fortune India 500 (2025).

Recognitions & Rankings of Torrent Pharma

Fortune India 500 2025 edition
Rank#229
Total income
₹11,814 Cr
Profit
₹1,911 Cr
Last year #220
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#54
Valuation
₹1,12,910 Cr
2023 #68 2022 #69 2021 #89
  • Headquarters Ahmedabad, India
  • Employees 16,012
  • Founders Chirag Patel
  • Stage Public
  • Sectors
    Healthcare
  • Website torrentpharma.com
  • Social LinkedIn Facebook
  • Legal Name Torrent Pharmaceuticals Ltd
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹1,79,807 Cr

    TORNTPHARM · NSE

  • Share Price
    ₹4,670.00

    -1.21% today

  • Revenue
    ₹19,274 Cr

    FY 2025-26 · +67.4% YoY

  • EBITDA
    ₹4,470 Cr

    Margin 23.2%

  • Net Profit
    ₹2,192 Cr

    FY 2025-26 · +14.4% YoY

  • P/E (TTM)
    83.8x

    P/B 9.9x

  • ROE
    26.8%

    ROCE 18.3%

  • Debt / Equity
    1.14

    Interest cover 11.5x

  • Latest Funding Round
    $40M (USD), Post-IPO

    Apr 2014

  • Investors
    ChrysCapital
  • Employee Count
    16,012
  • Investments & Acquisitions
    Bio-Pharm

    & 2 more

Funding Insights of Torrent Pharma

  • Total Rounds 2
  • Last Round Post-IPO — $40M
  • Investors Count 1

All 2 funding rounds of Torrent Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2014$40MPost-IPO––
ChrysCapital
Dec 2013Post-IPO––
ChrysCapital
Valuation history

1 investors in total: 1 institutional.

Investors in Torrent Pharma

Torrent Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ChrysCapital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
ChrysCapital
Investment firm focusing on private equity in sectors like financial services and healthcare.
1999chryscapital.com
Premium access

Investor details for Torrent Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Torrent Pharmaceuticals Ltd (Torrent Pharma)

Torrent Pharmaceuticals Ltd is the primary company behind Torrent Pharma. The board of Torrent Pharmaceuticals Ltd currently have 7 directors; the longest-serving is Samir Uttamlal Mehta, appointed in 2010. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Samir Uttamlal Mehta
DIN 00061903
Managing Director01 Aug 201016 yrs 3 moTorrent Pharmaceuticals Ltd
Nayantara Bali
DIN 03570657
Director07 Mar 20197 yrs 8 moTorrent Pharmaceuticals Ltd
Manish Mahendra Choksi
DIN 00026496
Director29 Jul 20224 yrs 3 moTorrent Pharmaceuticals Ltd
Aman Samir Mehta
DIN 08174906
Managing Director01 Aug 20224 yrs 3 moTorrent Pharmaceuticals Ltd
Nikhil Khattau Nirvan
DIN 00017880
Director01 Oct 20233 yrs 1 moTorrent Pharmaceuticals Ltd
Jinal Sudhirbhai Mehta
DIN 02685284
Director24 May 20242 yrs 5 moTorrent Pharmaceuticals Ltd
Shanti Ekambaram
DIN 00004889
Director30 Jul 20263 moTorrent Pharmaceuticals Ltd

People of Torrent Pharma

250 people are tracked at Torrent Pharma (59 in leadership, 8 in board & advisors, 183 in team); the tracked headcount is 16,012.

NameRoleGroup
Chirag Patel
Founder & CEOLeadership
Dr Dhaval Shah
General ManagerLeadership
Jignesh Bhatt
General ManagerLeadership
Manish Parikh
General ManagerLeadership
Vishal Bhatt
Asst General Manager - MktgLeadership
Sandeep Kulkarni
General ManagerLeadership
Reshmi Naik
Assistant General Manager Human ResourcesLeadership
Nilkamal Gadkari
General Manager Human Resources & AdministrationLeadership
Dr Chandrashekhar Tike
Cluster Head - Vice President Sales And MarketingLeadership
Naimikumar Kapashi
Vice President FinanceLeadership
Dr. Priti Shah
General ManagerLeadership
Dr. Nirav Shah
General Manager Sales MarketingLeadership
Aurobinda Panda
Assistant General Manager Human ResourcesLeadership
Pradeep Verma
Asst. General Manager - HRLeadership
Bhagwan Goswami
Head – HR | Leadership Development & Workplace Wellbeing | Mind Coach & Neuroleadership SpecialistLeadership
Dr. Pankaj Kumar Jha
Assistant General ManagerLeadership
Tarak Shah
General ManagerLeadership
Dr.manoj Prabhavat
General Manager -procurement ( Startegic Sourcing, Commercial Procurement And Contract ManufacturingLeadership
Krishna Shetty
Assistant General ManagerLeadership
Vijay Sitaram Pawale
General ManagerLeadership

230 more people are available in the full profile.

Premium access

Complete people profiles for Torrent Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Torrent Pharma

Torrent Pharma is a publicly listed company on the NSE with ticker symbol TORNTPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Nov 2002
  • Listed onNSE: TORNTPHARM
  • Listed entityTorrent Pharmaceuticals Ltd
  • Exchange sectorHealth technology
  • ISININE685A01028
  • Share price₹4,600.70 (-0.91% on the day) · 2026-10-14
  • Market capitalisation₹176,294 Cr
  • Price to earnings71.4
  • EPS (diluted, trailing year)₹64.44
  • Dividend yield0.81%
  • Volume (last session)100,259

Financials of Torrent Pharma

Exchange-reported figures of Torrent Pharmaceuticals Ltd, the listed company behind Torrent Pharma (NSE: TORNTPHARM).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹19,274 Cr
+67.4% YoY
EBITDA
₹4,470 Cr
+20.9% YoY
Profit After Tax
₹2,192 Cr
+14.4% YoY
Net Worth
₹8,388 Cr
+10.5% YoY
Total Assets
₹33,483 Cr
+196.1% YoY
Total Debt
₹15,026 Cr
+369.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19,27411,51610,7289,6208,5088,0057,939
Revenue growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
EBITDA4,4703,6973,3682,8421,9472,4802,170
EBITDA margin+23.2%+32.1%+31.4%+29.5%+22.9%+31.0%+27.3%
Profit before tax2,8722,6732,3521,8471,2261,5261,187
Net profit2,1921,9161,5811,2181,0761,2401,002
Net profit margin+11.4%+16.6%+14.7%+12.7%+12.7%+15.5%+12.6%
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
Balance sheet
Total assets33,48311,30911,33311,98210,40111,09411,065
Net worth8,3887,5916,8566,1985,9535,8374,823
Total debt15,0263,2024,0225,3694,0704,8745,784
Cash & bank1,165579839571403604667
Net working capital3,3672,6582,3992,5302,4762,4022,034
Cash flow
Cash from operations3,0232,5853,2662,3681,8032,0051,393
Cash from investing(12,630)(549)(160)(2,335)(196)(444)229
Cash from financing10,151(2,298)(2,780)77.36(1,781)(1,651)(1,549)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,9794,9214,1973,3033,3023,1782,9592,809
Revenue growth (YoY)+50.8%+54.9%+41.8%+17.6%+14.3%+11.2%--
Other income(10.00)(12.00)(17.00)(13.00)(27.00)(37.00)(18.00)33.00
EBITDA1,6561,6431,2901,0781,0701,032940914
EBITDA margin+33.8%+34.0%+31.3%+33.2%+33.0%+33.0%+32.3%+33.1%
Depreciation609593508206204201201199
Interest30030523645.0048.0056.0056.0057.00
Profit before tax737733529814791738665691
Tax203167165179200190167188
Net profit534566364635591548498503
EPS (₹)14.0514.8711.5118.7717.4516.1914.7114.88
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,7139,6838,5337,6956,7426,4516,168
Revenue growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
EBITDA3,9833,5522,8892,4652,1012,1921,917
EBITDA margin+37.2%+36.7%+33.9%+32.0%+31.2%+34.0%+31.1%
Profit before tax2,8972,6101,9171,5771,4661,3661,117
Net profit2,2131,8921,3421,0239851,125914
Net profit margin+20.7%+19.5%+15.7%+13.3%+14.6%+17.4%+14.8%
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
Balance sheet
Total assets23,18210,57410,46511,2989,91110,63510,667
Net worth8,4527,5926,8296,4566,3456,0305,121
Total debt14,2772,6293,3444,5753,3484,4045,294
Cash & bank82.9811010914869.4666.42391
Net working capital2,8972,7972,3452,5992,7012,8772,602
Cash flow
Cash from operations2,7312,5742,8932,2652,1401,5731,580
Cash from investing(12,990)(470)(296)(2,326)(160)(316)269
Cash from financing10,225(2,104)(2,578)80.74(1,977)(1,581)(1,555)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,1454,1583,4452,5992,7622,6162,4332,377
Revenue growth (YoY)+50.1%+58.9%+41.6%+9.3%+13.5%+7.3%--
Other income(11.00)(21.00)(30.00)(8.00)(27.00)(5.00)15.003.00
Total expenses2,5842,6062,2831,6091,7031,6371,5891,490
EBITDA1,5611,5521,1629901,059979844887
EBITDA margin+38.4%+38.1%+34.4%+38.9%+39.1%+38.1%+35.4%+38.1%
Depreciation587575490191189187190191
Interest28729322634.0037.0045.0047.0048.00
Profit before tax676663416757806742622651
Tax178171107180209191148166

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,9794,9214,1973,3033,3023,1782,9592,809
Revenue growth (YoY)+50.8%+54.9%+41.8%+17.6%+14.3%+11.2%--
Other income(10.00)(12.00)(17.00)(13.00)(27.00)(37.00)(18.00)33.00
EBITDA1,6561,6431,2901,0781,0701,032940914
EBITDA margin+33.8%+34.0%+31.3%+33.2%+33.0%+33.0%+32.3%+33.1%
Depreciation609593508206204201201199
Interest30030523645.0048.0056.0056.0057.00
Profit before tax737733529814791738665691
Tax203167165179200190167188
Net profit534566364635591548498503
EPS (₹)14.0514.8711.5118.7717.4516.1914.7114.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19,27411,51610,7289,6208,5088,0057,939
Revenue growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
Other income(93.58)23.2714645.1419756.91121
Total expenses14,8057,8197,3606,7786,5615,5245,769
Employee cost2,6712,2031,9841,6781,5261,4401,429
EBITDA4,4703,6973,3682,8421,9472,4802,170
EBITDA margin+23.2%+32.1%+31.4%+29.5%+22.9%+31.0%+27.3%
Depreciation1,119795808707662658654
Interest385252354333255353451
Profit before tax2,8722,6732,3521,8471,2261,5261,187
Tax734762696602449274162
Net profit2,1921,9161,5811,2181,0761,2401,002
Net profit margin+11.4%+16.6%+14.7%+12.7%+12.7%+15.5%+12.6%
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16916916916984.6284.6284.62
Reserves & surplus8,2197,4216,6876,0295,8685,7534,739
Shareholders' funds (net worth)8,3887,5916,8566,1985,9535,8374,823
Minority interest9,1960.000.000.000.000.000.00
Secured loans12,6842,2263,1504,5303,2954,3325,180
Unsecured loans2,342976872839775542605
Total debt15,0263,2024,0225,3694,0704,8745,784
Total liabilities33,48311,30911,33311,98210,40111,09411,065
Assets
Gross block40,42614,04113,48512,81210,72810,51210,334
Net block33,1917,9478,1388,1216,4237,0657,533
Capital work in progress641478361765630889712
Investments9481561731992261812.11
Inventories3,1382,5412,2792,2302,4622,6812,148
Sundry debtors3,0311,8661,8441,9441,6321,5231,649
Cash & bank balances1,165579839571403604667
Loans & advances1,192523508413483574515
Total current assets8,5265,5105,4705,1584,9815,3824,979
Total current liabilities5,1592,8523,0722,6282,5052,9812,945
Net working capital3,3672,6582,3992,5302,4762,4022,034
Total assets33,48311,30911,33311,98210,40111,09411,065
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash573835509398573662589
Net cash from operating activities3,0232,5853,2662,3681,8032,0051,393
Net cash from investing activities(12,630)(549)(160)(2,335)(196)(444)229
Net cash from financing activities10,151(2,298)(2,780)77.36(1,781)(1,651)(1,549)
Net change in cash544(262)327110(174)(89.26)73.06
Closing cash1,165579839571403604667
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
EBITDA growth+20.9%+9.8%+18.5%+46.0%-21.5%+14.3%-
PBT growth+7.5%+13.6%+27.3%+50.7%-19.7%+28.6%+111.3%
Net income growth+14.4%+21.2%+29.9%+13.1%-13.2%+23.7%-
Revenue CAGR (3Y)+26.1%+10.6%+10.3%+6.6%+3.5%+10.4%+10.9%
EBITDA CAGR (3Y)+16.3%+23.8%+10.7%+9.4%+6.2%+22.5%+16.4%
Profitability & leverage
Net income margin+11.1%+16.6%+15.4%+12.9%+9.1%+15.6%+12.9%
Return on capital employed+18.3%+25.8%+23.2%+19.5%+18.2%+17.0%+14.8%
Return on net worth+26.8%+26.5%+25.4%+20.5%+18.3%+23.5%+21.5%
Debt / equity1.140.500.720.780.761.001.24
Long-term debt / equity0.820.210.320.390.430.590.75
Interest cover11.498.6913.8115.6119.8619.3729.73
Efficiency & per share
Fixed asset turnover0.710.840.820.820.800.770.78
Inventory turnover6.794.784.764.103.313.313.89
Debtors turnover7.876.215.665.385.395.055.15
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
Dividend per share (₹)38.0032.0028.0022.0048.0035.0032.00
Book value per share (₹)247.84224.27202.57183.13351.75344.90284.99
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,1454,1583,4452,5992,7622,6162,4332,377
Revenue growth (YoY)+50.1%+58.9%+41.6%+9.3%+13.5%+7.3%--
Other income(11.00)(21.00)(30.00)(8.00)(27.00)(5.00)15.003.00
Total expenses2,5842,6062,2831,6091,7031,6371,5891,490
EBITDA1,5611,5521,1629901,059979844887
EBITDA margin+38.4%+38.1%+34.4%+38.9%+39.1%+38.1%+35.4%+38.1%
Depreciation587575490191189187190191
Interest28729322634.0037.0045.0047.0048.00
Profit before tax676663416757806742622651
Tax178171107180209191148166
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,7139,6838,5337,6956,7426,4516,168
Revenue growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
Other income17.9231.5091.3681.88204118237
Total expenses6,7306,1325,6445,2304,6424,2594,251
Employee cost1,8791,6361,4511,2511,0981,0971,062
EBITDA3,9833,5522,8892,4652,1012,1921,917
EBITDA margin+37.2%+36.7%+33.9%+32.0%+31.2%+34.0%+31.1%
Depreciation764759761672602610607
Interest341213303298236334430
Profit before tax2,8972,6101,9171,5771,4661,3661,117
Tax705722559526475228178
Net profit2,2131,8921,3421,0239851,125914
Net profit margin+20.7%+19.5%+15.7%+13.3%+14.6%+17.4%+14.8%
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16916916916984.6284.6284.62
Reserves & surplus8,2837,4236,6606,2876,2615,9455,036
Shareholders' funds (net worth)8,4527,5926,8296,4566,3456,0305,121
Secured loans12,4942,0552,9834,3663,1434,1854,991
Unsecured loans1,782574361210204219303
Total debt14,2772,6293,3444,5753,3484,4045,294
Total liabilities23,18210,57410,46511,2989,91110,63510,667
Assets
Gross block13,85713,30113,00012,36710,0029,9539,806
Net block7,3707,5547,9867,9726,2516,7417,198
Capital work in progress420402226698568588536
Investments13,172523463361368314135
Inventories1,5261,5611,5661,6021,7971,9121,508
Sundry debtors2,6412,1711,5721,7291,5411,5441,509
Cash & bank balances82.9811010914869.4666.42391
Loans & advances514395354292342480412
Total current assets4,7644,2373,6003,7713,7494,0033,819
Total current liabilities1,8671,4401,2551,1721,0481,1261,218
Net working capital2,8972,7972,3452,5992,7012,8772,602
Total assets23,18210,57410,46511,2989,91110,63510,667
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10510585.4065.0061.8738692.61
Net cash from operating activities2,7312,5742,8932,2652,1401,5731,580
Net cash from investing activities(12,990)(470)(296)(2,326)(160)(316)269
Net cash from financing activities10,225(2,104)(2,578)80.74(1,977)(1,581)(1,555)
Net change in cash(34.14)(0.05)19.4620.403.13(325)294
Closing cash82.9811010914869.4666.42391
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
EBITDA growth+12.2%+22.9%+17.2%+17.4%-4.2%+14.3%-
PBT growth+11.0%+36.2%+21.5%+7.6%+7.3%+22.3%+19.4%
Net income growth+16.9%+41.0%+31.2%+3.9%-12.5%+23.1%-
Revenue CAGR (3Y)+11.7%+12.8%+9.8%+7.7%+5.4%+15.0%+10.7%
EBITDA CAGR (3Y)+17.3%+19.1%+9.7%+8.7%+9.2%+34.2%+19.4%
Profitability & leverage
Net income margin+20.5%+19.5%+15.9%+13.7%+14.7%+17.6%+15.2%
Return on capital employed+19.2%+26.8%+20.4%+17.7%+16.6%+16.0%+14.4%
Return on net worth+27.3%+26.2%+20.4%+16.4%+16.0%+20.4%+18.5%
Debt / equity1.050.410.600.620.630.871.08
Long-term debt / equity0.790.190.300.340.400.540.68
Interest cover10.597.6414.2416.6015.7721.1232.85
Efficiency & per share
Fixed asset turnover0.790.740.670.690.680.650.64
Inventory turnover6.946.195.394.533.643.774.30
Debtors turnover4.455.175.174.714.374.234.31
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
Dividend per share (₹)38.0032.0028.0022.0048.0035.0032.00
Book value per share (₹)249.72224.32201.76190.75374.94356.30302.59

Investments & Acquisitions by Torrent Pharma

Torrent Pharma has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Bio-Pharm, Curatio healthcare and JB.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
JB
Generic drugs are manufactured by JB in Mumbai, India.
jbpharma.comMumbai, India1976Jun 2025$1.39B
Curatio healthcare
Market research services for biopharma sector are provided.
curatiohealthcare.comChennai, India2005Sep 2022$244.72M
Bio-Pharm
Generic drugs are manufactured by Bio-Pharm in the United States.
bio-pharminc.comLevittown, United States1992Jan 2018••••
Premium access

Complete acquisition details for Torrent Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Torrent Pharma

7 dated milestones of Torrent Pharma across 66 years, from founding to its latest funding, stage changes and deals.

  1. Founded Torrent Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round.
  4. Funding Latest funding round, Post-IPO, of $40.0M.
  5. Acquisition Acquires Bio-Pharm.
  6. Acquisition Acquires Curatio healthcare.
  7. Acquisition Acquires JB.

Web traffic of Torrent Pharma

The website of Torrent Pharma (torrentpharma.com) receives about 31.6K visits a month.

  • Monthly visits
    31.6K

    ▼ 2.6% vs previous month

Similar websites

Websites whose visitors overlap most with Torrent Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Sun Pharma
sunpharma.com
100%
216K#177,160View details
Cipla
cipla.com
93%
200.9K#203,362View details
GSK
gsk.com
93%
1.3M#56,834View details
alembic-india.com
alembic-india.com
93%
–
JB
jbpharma.com
91%
21.3K#1,273,522View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Torrent Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Torrent Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Torrent Pharma

TORNTPHARM: Rs. 27.78 Crores BSE Block Trade; for ~ 60,000 Shares, at Rs. 4630.00
Exchange Update • 17 days ago
Torrent Pharma: Kotak Institutional Equities on Torrent Pharma Upgrades to Buy, Target Price ₹5,665; Q2 was in line, with strong double-digit base-business growth offset by slower JB Pharma, Germany and higher R&D costs. JB cost synergies reached ₹1.2bn in H1, ahead of schedule, with revenue synergies expected from Q1FY28; forecasts 19% FY26–29 EBITDA CAGR.
Exchange Update • 18 days ago
Torrent Pharma: HSBC on Torrent Pharma Maintains Buy, Target Price ₹5,700; base India sales excluding JB Pharma rose 20% YoY, while JB performance was affected by post-merger integration. Branded-generics growth should support margin expansion, and recovery in JB Pharma's portfolio is the next catalyst.
Exchange Update • 18 days ago
Torrent Pharma: Citi on Torrent Pharma Maintains Buy, Target Price ₹5,860; Q2 was in line, with strong India and Brazil performance offset by temporary JB integration and delayed international deliveries. Management expects gradual JB recovery and improving H2 India growth; around half of the ₹4.5bn synergies are expected in FY27, with the balance in FY28.
Exchange Update • 18 days ago
Torrent Pharma: Jefferies on Torrent Pharma Maintains Buy, Target Price ₹5,900; India base business grew 20% YoY and Brazil delivered 21% constant-currency growth, while US growth remained steady. JB integration is ahead of schedule, with half of cost synergies achieved and revenue synergies expected to support next year's growth.
Exchange Update • 18 days ago
Torrent Pharma: Nomura on Torrent Pharma Maintains Neutral, Target Price ₹5,030; Q2 headline performance slightly missed expectations, but core business remained strong. The company now expects ₹4.5bn of JB Pharma acquisition synergies over two years instead of three, with margins expected to improve slightly in H2FY27 as operations stabilise.
Exchange Update • 18 days ago
TORNTPHARM: Q2 REVENUE 49.79B RUPEES VS 33B (YOY); EST 49.06B
Exchange Update • 21 days ago
TORNTPHARM: Q2 CONS NET PROFIT 5.34B RUPEES VS 5.9B (YOY); EST 5.4B
Exchange Update • 21 days ago
TORNTPHARM: Q2 EBITDA 16.56B RUPEES VS 10.8B (YOY), EST 16.25B; Q2 EBITDA MARGIN 33.26% VS 10.8B% (YOY), EST 33%
Exchange Update • 21 days ago
Torrent Group to build 800-bed hospital & medical college in South Gujarat at ₹910 cr - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Premium access

Complete news archive for Torrent Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Torrent Pharma on our blog

Frequently Asked Questions about Torrent Pharma

Torrent Pharma was founded in 1959 and raised its 1st funding round 54 years after it was founded.

Torrent Pharma is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Chirag Patel is the CEO of Torrent Pharma, as recorded in our data. They have also founded this company.

Torrent Pharma has 16,012 employees.

The primary company behind Torrent Pharma, Torrent Pharmaceuticals Ltd, reported revenue of ₹10,730 Cr for FY 2026, up 67% year on year.

Torrent Pharma was established in 1959 in Ahmedabad, India, within the pharmaceutical sector. Formulations and active pharmaceutical ingredients (APIs) are developed, alongside drug discovery efforts. Marketing and sales operations are managed to support product distribution. Services extend across domestic and international markets, with the companys online presence maintained at torrentpharma.com. Leadership is provided by founder and CEO Chirag Patel.

Yes, Torrent Pharma is publicly traded on NSE under the ticker symbol TORNTPHARM.

Torrent Pharma has made 3 acquisitions, including Bio-Pharm, Curatio healthcare, and JB.

Torrent Pharma has 1 investor. Key investors include ChrysCapital.

Torrent Pharma operates through Torrent Pharmaceuticals Ltd.

The legal entities of Torrent Pharma currently have 9 directors, including Samir Uttamlal Mehta, Nayantara Bali, Manish Mahendra Choksi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available